ODAC Briefing Document Remestemcel-L: CMC
7
trials submitted to support licensure. While remestemcel-L and other MSC-based investigational
products have demonstrated apparent immunomodulatory effects in in vitro experiments, the
ability of remestemcel-L to reduce inflammation as measured by inflammatory biomarkers in
humans receiving the product has not been demonstrated. SR-aGVHD is thought to be an
immune-mediated disorder but its etiology is complex and many cell types are likely to be
involved in its pathogenesis. Therefore, any efficacy remestemcel-L might have in treating this
disease is not sufficient to demonstrate the product’s mechanism of action.
- Forums
- ASX - By Stock
- MSB
- Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C, page-58
-
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.21 |
Change
-0.093(7.09%) |
Mkt cap ! $1.364B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $9.652M | 7.819M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 6483 | $1.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.22 | 45988 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 72125 | 1.210 |
9 | 33365 | 1.205 |
15 | 93080 | 1.200 |
10 | 124967 | 1.195 |
6 | 51119 | 1.190 |
Price($) | Vol. | No. |
---|---|---|
1.215 | 40229 | 7 |
1.220 | 71346 | 12 |
1.225 | 109247 | 11 |
1.230 | 79673 | 10 |
1.235 | 41246 | 7 |
Last trade - 11.10am 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online